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Abstract
Background/Aim: To explore the therapeutic effects of thymidine kinase (TK) expressed by enhanced vector pGL3-
basic- hTERTp-TK-EGFP-CMV driven by human telomerase reverse transcriptase promoter (hTERTp) as well as
cytomegalovirus immediate early promoter enhancer (CMV).
Materials/Methods: Enhanced TK-EGFP expression was confirmed by fluorescent microscopy, real time PCR and
telomerase activity. Its effects were examined by survival of tumor cells NPC 5-8F and MCF-7, index of xenograft
implanted in nude mice and histology.
Results: Compared with non-enhanced vector pGL3-basic-TK-hTERTp-EGFP, TK expressed by the enhanced vector
significantly decreased NPC 5-8F and MCF-7 cell survival rates after ganciclovir (GCV) treatment (p < 0.001) and
tumor progress in nude mice with NPC xenograft and treated with GCV, without obvious toxicity to mouse liver
and kidney.
Conclusion: The enhanced TK expression vector driven by hTERTp with CMV enhancer has brighter clinical
potentials in nasopharyngeal carcinoma therapy than the non-enhanced vector.
Introduction
N a s o p h a r y n g e a lc a r c i n o m a( N P C )i so n eo fh i g h l yp r e -
valent, most harmful malignant tumors in Southern
China and Southeast of Asia. It is caused by the interac-
tion between genetic background and environmental
factors such as Epstein-Barr virus. At present, radiother-
apy and/or induction chemotherapy is the mainstay of
treatment modalities. Despite continuously progress in
radiotherapeutic equipment and technology, the 5-year
survival rate of NPC remains about 50% without funda-
mental improvement over the past several decades.
Understanding the etiology and developing new effective
therapeutic modality are particularly important in NPC
treatment.
Suicide gene therapy is a promising modality for
cancer treatment. Such therapy introduces a drug
susceptible gene such as herpes simplex virus thymidine
kinase (TK) gene into tumor cells. Expressed TK phos-
phorylates its substrate, a nontoxic prodrug ganciclovir
(GCV), leading to accumulation of the toxic ganciclovir
triphosphate and cell apoptosis. The ideal suicide gene
expression constructs should have high specificity and
killing efficacy to tumor cells. To selectively introduce
suicide gene into tumor cells, many tumor specific pro-
moters have been employed to construct tumor-specific
suicide gene expression vectors.
Human telomerase reverse transcriptase (hTERT), the
core component of telomerase, plays important roles in
vast majority of malignant tumors including nasophar-
yngeal carcinoma. The telomerase activity and level of
hTERT expression are enhanced in all nasopharyngeal
carcinoma cell lines and 88% nasopharyngeal tissues.
Their activities are closely correlated with clinical biolo-
gical characteristics of nasopharyngeal carcinoma[1,2].
Therefore, telomerase/hTERT is utilized as a targeted
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promoter has been widely employed to drive the tumor-
specific expression of exogenous genes. For example,
Wang et al[3] and Zhang et al [4] constructed vectors
pGL3-hTp-TK/GCV and TERT-E1A-TK, respectively,
both of which can kill lung cancer cells and transplanted
tumor in vitro and in vivo. Zheng et al [5] constructed
vector pHSV-TK/CRAD, which can significantly
enhance the killing effect of GCV on liver cancer in ani-
mal. Shen et al [6] selectively expressed shRNA in naso-
pharyngeal carcinoma cells by introducing hTERT,
which successfully inhibited telomerase activity and
induced cell apoptosis. We [7] have reported previously
that administration of antisense oligodeoxynucleotide of
telomerase RNA (hTR) and hTERT subunit can inhibit
telomerase in tumor cells and induce tumor cell apopto-
sis. Recently, we [8,9] exploited the hTERT promoter to
construct pGL3-hTERTp-TK vector and introduced the
vector into NPC tumor cells in vitro and in vivo in mice
xenograft, which killed NPC tumor cells and xenograft
without observing toxicity to liver and kidney. However,
its tumor killing efficacy is less than that of non-TK tar-
geted system driven by cytomegalovirus immediate early
promoter (CMV). To further increase TK mediated
tumor killing efficacy and facilitate tracing TK expres-
sion, we constructed a new vector by inserting a CMV
enhancer and an EGFP reporter gene into pGL3-
hTERTp-TK vector, and evaluated its therapeutic effi-
cacy in in vitro and in vivo tumor therapy.
Materials and methods
1. Reagents
Fetal bovine serum (FBS) was purchased from Hang-
zhou Sijiqing Company. PCR kit and TaqMan real time
PCR kit were from Takara Bio-engineering Co., Ltd. 3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) was from Sigma, USA; Ganciclovir (GCV)
was from ROCH company. Lipofectamine 2000, DMR
IE2C and Trizol were from Invitrogen. TRAPEZE® RT
telomerase activity detection kit was purchased from
KeyGen (Nanjing, China). Plasmid Midi Kit was from
Heda Biotech (Guangzhou, China). All PCR primers
were synthesized by Shanghai Ying-Jun Biotechnology
Co., Ltd.
2. Cell lines
Human nasopharyngeal carcinoma 5-8F cells (NPC 5-
8F), human breast cancer cells MCF-7 and human vas-
cular endothelial cells ECV were kindly provided by
Department of Cell Biology, the Southern Medical Uni-
versity, and maintained in RPMI 1640 supplemented
with 10% heat-inactivated fetal bovine serum at 37°C in
a5 %C O 2 incubator (Shell LAB, USA) as previously
reported [10].
3. Construction of plasmid with luciferase reporter gene
EGFP gene was obtained from pEGFP-N1 by PCR using
forward primer Egfp-F: CCCAAGCTTATGGTGAG-
CAAGGGCGAGGAG and reverse primer Egfp-R:
GCTCTAGATTACTTGTACAGCTCGTCCATGC. 406
bp CMV enhancer fragment was obtained from pEGFP-
N1 by PCR using forward primer hCMVen-F: 5-
CGGGATCCCGCGTTACATAACTTACGGT-3′ and
reverse primer hCMVen-R: 5-ACGCGTCGACCAAAA-
CAAACTCCCATTGAC-3. 1131 bp TK gene with NCBI
accession number AY575228 was obtained from pMD18-
TK by PCR using forward primer 5-CCGCTCGA-
GATGGCTTCGTACCCCTGC-3′ and reverse primer 5-
CCCAAGCTTGTTAGCCTCCCCCATCTC-3. The 260
bp hTERT promoter was obtained from pMD18-
T-hTERTp using forward primer hTERTp-F: 5-
GGGGTACCAGTGGATTCGCGGGCACAGACG-3′
and reverse primer hTERTp-R: 5-CCGCTCGA-
GAGGGCTTCCCACGTGCGCAGCA-3. All PCR frag-
ments were verified by DN
A sequence analysis. Stop codon TGA of TK
gene was removed in TK reverse primer to
facilitate the construction of TK-EGFP fusion
protein. EGFP fragment was digested with
Hind III and Xba I and subcloned into pGL3-
basic plasmid to obtain pGL3-basic-EGFP. TK
fragment was excised with Hind III and Xho I
and subcloned into pGL3-basic-EGFP to con-
struct pGL3-basic- TK-EGFP. hTERTp frag-
ment was subcloned into pGL3-basic-TK-EGFP
at Kpn I and Xho I sites to construct pGL3-
basic-TK-hTERTp-EGFP. CMV enhancer frag-
ment was inserted into pGL3-basic-TK-
hTERTp-EGFP at BamH I and Sal I site
according to previous reports [11,12] to con-
struct the enhanced vector pGL3-basic-
hTERTp-TK- EGFP-CMV. All plasmids were
verified by restriction enzyme digestion.
4. Cell transfection as well as expression of TK-EGFP
fusion protein
1×1 0
6 NPC 5-8F, MCF-7 and ECV cells at logarithmic
phase were inoculated into one well of 6-well plate with
duplications, respectively. 12 hours after inoculation,
cells at about 80% confluency were transfected with 4
μg of plasmid pGL3-basic-hTERTp-TK-EGFP-CMV or
pGL3-basic-hTERTp-TK-EGFP by mixed with 4 μl
Lipofectamine 2000 according to the protocol provided
by the manufacturer. 24 hours after transfection, the
expression of TK-EGFP fusion protein was directly
observed with fluorescent microscopy (Nikon Eclipsete
2000-U, USA).
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Page 2 of 95. RNA Isolation and TK mRNA level detection by
quantitative real-time PCR
48 hours after transfection, total RNA was extracted
with Trizol (Invitrogen) following the manufacturer’s
instruction. 4 μL mRNA of each sample was used as
template in quantitative real-time PCR performed in an
ABI 7500 Real-Time PCR system using Taqman PCR
kit based on the manufacturer’s protocol. The specific
primers used in these reactions were followings: TK for-
ward 5′-AGCAAGAAGCCACGGAAGTC-3′ and reverse
5′-AGTTGCGTGGTGGTGGTTTT-3′;h u m a nb-actin
forward 5′-GCATGGGTCAGAAGGATTCCT-3′ and
reverse 5′-TCGTCCCAGTTGGTGACGAT-3′. Relative
levels of TK gene expression were normalized to b-actin
mRNA level.
6. Telomerase activity measurement
NPC 5-8F cells at logarithmic phase were inoculated
into three wells of a 6-well plate with 1 × 10
6/well.
Twelve hour later, two wells of cells were transfected
with 8 μg pGL3-basic- hTERTp-TK-EGFP-CMV plas-
mid. Twelve hours after transfection, one well of cells
transfected with pGL3-basic-hTERTp-TK-EGFP-CMV
were treated with 10 μg/mL GCV. 48 hours after drug
treatment, telomerase activities of all three well of cells
were measured using PCR-based TRAP telomerase
activity detection kit. As control, telomerase activity of 1
×1 0
6 ECV cells at logarithmic phase was also detected
using the same method. The PCR products were sepa-
rated on 12% non-PAGE and visualized by silver stain.
7. Cell survival rate measurement by MTT method
NPC 5-8F cells at logarithmic phase were inoculated into
15 wells of 96-well plate with 1 × 10
5 cells in each well.
Twelve hours later, 3 wells of NPC 5-8F cells were used as
blank, 3 wells were transfected with 2.4 μgp G L 3 - b a s i c -
EGFP as control, 6 wells were transfected with pGL3-
basic- hTERTp-TK-EGFP-CMV. Twelve hours after trans-
fection, control group and three wells of the cells trans-
fected with pGL3-basic-hTERTp-TK-EGFP-CMV were
treated with 10 μg/mL GCV. 72 hours after treatment, all
cells were subjected to MTT assay as described previously
[10]. In detail, 20 μl of 5 g/L MTT solution was added
into each well of the 96-well plate, and the plate was incu-
bated for 4 hours at room temperature. After the culture
solution was removed, 150 μl DMSO was added into each
well and oscillated for 10 minutes. Then the absorption at
570 nm was measured with Startfax 2100 microplate
reader (USA). Cell survival rate was expressed as A/
B×100%, where A was the absorption from cells trans-
fected with plasmid and treated with or without GCV, and
B was that from the blank group.
T h es a m ee x p e r i m e n tw a sp e r f o r m e du s i n gM C F - 7
cells instead of NPC 5-8F cells.
8. In vivo animal experiments
Healthy male and female nude BALB/c nu/nu mice of
age 4-5 weeks, weighing between 18-22 g, were from
the Experimental Animal Centre of The Southern Medi-
cal University, and maintained in a SPF level aseptic
environment. The animals were free access to aseptic
rodent diet and water. The protocol of animal experi-
ments was approved by ethical and humane committee
of Zhujiang Hospital, The Southern Medical University.
NPC 5-8F cells at logarithmic phase were prepared as
5×1 0
6 cells/mL single cell suspension in phosphate
buffered saline (PBS) and 0.2 ml of cell suspensions
were subcutaneously inoculated into the left flank of
BALB/c nude mice. The cancer growth was monitored
every 3 days starting at the day after inoculation by cali-
pers to record the length (a) and width (b), and tumor
volume were calculated by the formula V = 1/2 (a × b
2).
When majority tumors reached 1.2 ~ 1.5 cm in dia-
meter at day 10 after inoculation, nude mice were ran-
domly divided into 6 groups: blank group,
Lipofectamine group, non-enhanced group, enhanced
group, enhanced/GCV group, and GCV group. Mice in
blank and GCV groups were intratumorally injected
with PBS; mice in Lipofectamine group were intratumo-
rally injected 25 μL Lipofectamine alone; mice in non-
enhanced group were intratumorally injected with mix-
ture of 25 μL Lipofectamine with 10 μg plasmid pGL3-
basic-hTERTp-TK-EGFP; mice in enhanced and
enhanced/GCV groups were injected with the mixture
of 25 μL Lipofectmine 2000 and 10 μg plasmid pGL3-
basic-hTERTp-TK-EGFP-CMV. All injections were per-
formed repeatedly at the days 4, 7, 10 and 14 after the
first injection. Meanwhile, mice in GCV and enhanced/
GCV groups were intraperitoneally injected 100 mg/kg
bodyweight GCV every 2 days starting at day 1 after the
first injection of the mixture for total 12 times. When
the tumor volume reached 6 cm
3 in mice from blank
group, all mice were sacrificed by cervical dislocation
and the whole tumors were removed and weighed, and
livers and kidneys from mice in Lipofectamine,
enhanced/GCV and GCV groups were preserved for
further histopathological examination. The inhibition
rate of different treatment on tumor growth was calcu-
lated according to the following formula:
Tumor inhibition rate  tumor weight in non treatment g (%) ( =− r roup tumor weight in treatment group
                   
− )/
                                                tumor weight t in non treatment group −× 100.
9. Histopathological examination
The preserved livers and kidneys were fixed with 10%
formaldehyde solution and the sections were stained
with hematoxylin and eosin, and analyzed by light
microscopy.
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Page 3 of 910. Statistical analysis
Data were analyzed with SPSS11.0 statistical software
and expressed as mean ± standard deviation. Statistical
significant was analyzed using one-way ANOVA and
q test. A p value less than 0.05 was considered as statis-
tical significance.
Results
1. Identification of pGL3-basic- hTERTp -TK-EGFP-CMV
plasmid
We constructed an enhanced TK expression vector as
described in the Materials and Methods section. First
we examined whether we successfully constructed the
enhanced TK expression vector. Digestion with BamH I
and Sal I, Xho I and Xba I, Kpn I and Hind III resulted
in 406 bp, 1850 bp and 1400 bp fragments, respectively,
as expected. The sequences of TK gene, hTERTp and
CMV enhancer have been confirmed by direct DNA
sequences.
2. Fluorescent level of TK-EGFP gene expression
Then we measured the fluorescent level of TK-EGFP
gene expression in NPC 5-8F and MCF-7 cells trans-
fected with either the enhanced plasmid pGL3-basic-
hTERTp-TK-EGFP-CMV or the non-enhanced pGL3-
basic-hTERTp-TK-EGFP by observing the fluorescent
intensity of co-expressed GFP under fluorescent micro-
scope. As shown in Figure 1, NPC 5-8F and MCF-7
cells transfected with the enhanced plasmid showed
very strong green fluorescence (Figure 1a and 1b).
NPC 5-8F cells transfected with the non-enhanced
plasmid also had very strong green fluorescence (Fig-
ure 1c). However, compared with cells transfected with
the enhanced plasmid, the fluorescent intensity was
decreased. ECV cells transfected with the enhanced
plasmid only showed weak, flurry fluorescence (Fig-
ure1d) under the same condition. Since the expression
of TK-EGFP was controlled by hTERT promoter,
therefore it was only expressed in telomerase-positive
cells. Furthermore, TK was fused to EGFP, expression
level of EGFP not only reflected the transfection effi-
cient, but also indirectly indicated the relative expres-
sion level of TK.
3. Enhanced TK mRNA level in cells transfected with
pGL3-basic-hTERTp-TK- EGFP-CMV
We further quantitatively examined the expression of
TK gene in NPC 5-8F and MCF-7 cells at mRNA level
by real-time PCR. Figure 2 showed the amplification
curves of housekeeping gene (b-actin and TK gene, and
Table 1 showed the relative expression level of TK gene
to (b-actin gene. TK gene expression in NPC 5-8F,
MCF-7 and ECV cells transfected with the enhanced
plasmid was 4.2-fold, 2.5-fold, and 0.0027-fold of b-
actin, respectively. By contrast, the TK expression level
in NPC 5-8F cells transfected with pGL3-basic-
hTERTp-TK-EGFP was only 0.82-fold of b-actin. No TK
expression was detected in NPC 5-8F cells transfected
with pGL3-basic-EGFP as expected. These results are
consistent with that of Figure 1.
4. Reduced telomerase activity by pGL3-basic-hTERTp-TK-
EGFP-CMV/GCV
Next we examined telomerase activity in PNC 5-8F cells
transfected with the enhanced plasmid with or without
GCV treatment. NPC 5-8F cells transfected with the
enhanced plasmid were telomerase activity positive.
H o w e v e r ,t h et e l o m e r a s ea c t i v i t yw a sd e c r e a s e db y4 8
hours of GCV treatment. As control, ECV cells showed
weak telomerase positive (Figure 3).
5. Decreased survival rate of tumor cells transfected with
the enhanced plasmid and treated with GCV
Having confirmed that transfection of the enhanced plas-
mid increased the expression of TK, we further studied
whether transfection of the enhanced plasmid could
affect the effect of GCV on the survival rate of nasophar-
yngeal carcinoma NPC 5-8F cells and breast cancer
MCF-7 cells by using MTT method. As shown in Tables
2 and 3, compared with non-transfected, untreated cells,
Figure 1 TK gene expression detected with fluorescent microscopy. Shown here are the cells 24 hours after transfection under fluorescent
microscope (×100). (a) NPC 5-8F cells transfected with pGL3-basic-hTERTp-TK-EGFP-CMV; (b) MCF-7 cells transfected with pGL3-basic-hTERTp-TK-
EGFP-CMV; (c) NPC 5-8F cells transfected with pGL3-basic-TRETp-TK-EGFP; (d) ECV cells transfected with pGL3-basic-hTERTp-TK- EGFP.
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Page 4 of 9transfection of control plasmid pGL3-basic-EGFP had no
effect on survival rates of tumor cells 5-8F and MCF-7
with GCV treatment, and transfection of the enhanced
plasmid pGL3-basic- hTERTp-TK-EGFP-CMV alone did
not change the survival rates of tumor cells NPC 5-8F
and MCF-7. However, after GCV treatment, survival
rates of NPC 5-8F and MCF-7 cells transfected with the
enhanced plasmid decreased to 0.370 ± 0.024 and 0.462
± 0.049, respectively, which was significantly lower than
that, 0.533 ± 0.020 and 0.515 ± 0.025, of tumor cells NPC
5-8F and MCF-7 transfected with the plasmid pGL3-
basic-hTERTp-TK- EGFP and treated with GCV,
respectively.
6. Injection of pGL3-basic-hTERTp-TK-EGFP-CMV/GCV
inhibited tumor progress in vivo
Then we explored whether injection of pGL3-basic-
hTERTp-TK-EGFP -CMV/GCV could inhibit tumor
progress. As showed in Figure 4 and table4, nude mice
inoculated NPC 5-8F cells developed tumor with volume
of 6.23 ± 0.04 cm
3 and weight of 2.68 ± 0.02 g. After
injection of non-enhanced plasmid and GCV, the tumor
volume and weight decreased to 3.51 ± 0.02 cm
3 and
1.51 ± 0.01 g (p = 0.000), respectively. In comparison,
after injection of the enhanced plasmid and GCV, the
tumor volume and weight decreased to 2.27 ± 0.02 cm
3
and 1.17 ± 0.01 g, respectively, which were significantly
lower than those of nude mice injected with the non-
enhanced vector (p = 0.000). The inhibition rates of
tumor progress were 43.68% and 56.34% for injection of
non-enhanced and enhanced plasmids, respectively.
Figure 2 Amplification curves of fluorescence quantitative PCR. Shown are the amplification curves of b-actin (a) and TK gene (b) from NPC
5-8F cells transfected with pGL3-basic-hTERTp-TK-EGFP-CMV plasmid (1), from MCF-7 transfected with pGL3-basic-hTERTp-TK-EGFP-CMV plasmid
(2), from NPC 5-8F cells transfected with pGL3-basic-hTERTp-TK-EGFP plasmid (3), from NPC 5-8F cells transfected with pGL3-basic-TK-EGFP
plasmid (4), and from ECV cells transfected with pGL3-basic-hTERTp-TK-EGFP-CMV plasmid (5).
Table 1 Expression of TK gene detected with real-time
PCR
Sample Copy number
(b-actin)
Copy number
(TK)
Relative folds to b-actin
1 6.67E+07 2.78E+08 4.16792*
2 4.50E+07 1.13E+08 2.51111**
3 7.76E+07 2.17E+05 0.00279639
4 8.21E+07 Undetermined Undetermined
5 1.69E+08 1.39E+08 0.822485
Numbers 1, 2, 3, 4, 5 correspond to the numbers in Figure 3.
1: NPC 5-8F cells transfected with pGL3-basic- hTERTp-TK- EGFP- CMV;
2: MCF-7 transfected with pGL3-basic- hTERTp-TK- EGFP- CMV;
3: NPC 5-8F cells transfected with pGL3-basic- hTERTp-TK- EGFP;
4: NPC 5-8F cells transfected with pGL3-basic -TK-EGFP;
5: ECV cells transfected with pGL3-basic- hTERTp-TK- EGFP- CMV.
Data are presented as mean ± standard deviation from these experiments. *P
< 0.0001 for sample 1 vs sample 3, sample 1 vs sample 5 and sample 2 vs
sample 3. **P < 0.001 for sample 2 vs sample 5.
Figure 3 GCV treatment down-regulates telomerase activity in
5-8F cells transfected with pGL3-basic-hTERTp-TK-EGFP-CMV.
Shown are the silver stain visualized PCR products of telomerase
activities assay by PCR-based TRAP telomerase activity detection kit
from NPC 5-8F cells transfected with enhanced plasmid pGL3-basic-
hTERTp-TK-EGFP-CMV (lane 1), NPC 5-8F cells without transfection
(lane 2), 5-8F cells transfected with pGL3-basic-hTERTp-TK-EGFP-CMV
and treated with GCV (lane 3), and ECV cells itransfected with pGL3-
basic-hTERTp-TK-EGFP-CMV and treated with GCV (lane 4).
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Page 5 of 97. Injection of pGL3-basic-hTERTp-TK-EGFP-CMV/GCV had
no toxicity to liver and kidney of nude mice
We further examined whether injection of GCV and the
enhanced plasmid could have any toxicity to nude
mouse. No obvious damages were observed in H&E
stain in the livers and kidneys from nude mice in GCV/
enhanced, GCV and Lipofectamine 2000 groups.
Discussions
Molecularly targeted therapy is a promising research
area in cancer therapy. Application of suicide gene in
tumor therapy was limited due to lack of selectivity. Sui-
cide gene TK or CD expression system driven by tumor-
specific promoter has overcome the disadvantage and
become a powerful modality in cancer therapy.
Identification of molecular targets is the key in mole-
cularly targeted therapy. Molecules involved in carcino-
genesis, cancer gene mutation, tumor angiogenesis and
tumor signal transduction, telomerase, and growth fac-
tors such as epidermal growth factor are potential tar-
gets for tumor treatment. Gene mutation [13], EB virus
[14], telomerase [1] and nasopharyngeal cancer stem
cells [10,15,16] are reportedly involved in the progress
of nasopharyngeal cancer. Therapies targeted to the
molecules and molecules related to those mentioned
above have made primary progress in nasopharyngeal
cancer treatment [14,8,10]. We have found that intro-
duction of TK expression vector driven by hTERT pro-
moter (hTERTp/TK) could kill nasopharyngeal
carcinoma cells, nasopharyngeal carcinoma stem cells,
and nasopharyngeal tumor xenograft in nude mice with-
out side effects on cultured normal cells and damaging
mouse liver and kidney functions [17]. Studies on other
tumors also confirmed the efficacy of hTERTp/TK for
cancer therapy. Introduction of herpes simplex TK gene
expression virus vector driven by hTERT promoter
(AdhTERT/TK) can specifically kill the undifferentiated
thyroid tumor and thyroid tumor xenograft in nude
mice, enhance the tumor GCV sensitivity without toxic
reaction in liver and the whole body examined by liver
pathology and serum enzymology [18]. By contrast,
introduction of TK gene expression vector driven by
CMV promoter (CMV/TK) not only kills tumor xeno-
graft, but also demonstrates obvious liver pathological
changes and damaged liver function revealed by serum
enzymology. In addition, hTERT promoter has been
used to target other tumor killing factors, such as cas-
pase 8, TRAIL and Bax, and subsequently induces
tumor specific apoptosis [19,18,20-23] and enhances the
sensitivity of tumor cells to GCV without adverse effect.
Thus, targeted gene therapy remains a highly promising
system and progress in this field is gaining momentum.
An ideal targeted vector should have both good tumor
specificity and high killing efficacy. To improve the kill-
ing efficacy, double suicide gene, dual-promoter, a pro-
moter plus an enhancer and double enhancers, etc. have
been employed. Kong et al [24] have exploited adeno-
virus-mediated TK/CD double suicide genes, which are
more effective in killing breast cancer cells in vitro.
Huang et al [25] have excised TK/CD suicide gene ther-
apy with combination of radiotherapy to enhance radio-
sensitivity of tumor. Liao et al [26] have found that
radiation can enhance therapeutic efficacy of hTERTp-
mediated gene therapy. But hTERT/CMV dual promoter
vector can not increase the activity of the promoter due
to possible interference between two promoters result-
ing in the decreased efficacy. CMV enhancer has been
widely used to improve the suicide gene expression dri-
ven by hTERT promoter and has application potentials
in targeted cancer gene therapy. Wang [11] has explored
Table 2 PNPC cell survival rates measured by MTT assay
Codes and Samples Survival rates
A. Cells without treatment 1
B. Cells transfected with pGL3-basic-EGFP and with GCV treatment 0.984 ± 0.009
C. Cells transfected with pGL3-basic- hTERTp-TK-EGFP-CMV and treated with GCV 0.370 ± 0.024*
D. Cells transfected with pGL3-basic-hTERTp-TK-EGFP-CMV without GCV 0.982 ± 0.010
E. Cells transfected with pGL3-basic-hTERTp-TK-EGFP and treated with GCV 0.533 ± 0.020*
Data are expressed as mean ± standard deviation from three experiments. * indicates p < 0.0001 compared with other groups
Table 3 MCF-7 cell survival rates measured by MTT assay
Codes and Samples Survival rates
A. Cells without treatment 1
B. Cells transfected with pGL3-basic-EGFP and with GCV treatment 0.987 ± 0.006
C, Cells transfected with pGL3-basic-hTERTp-TK-EGFP-CMV and treated with GCV 0.462 ± 0.049*
D. Cells transfected with pGL3-basic-hTERTp-TK-EGFP-CMV without GCV 0.984 ± 0.011
E. Cells transfected with pGL3-basic-hTERTp-TK-EGFP and treated with GCV 0.515 ± 0.025*
Data are expressed as mean ± standard deviation from three experiments. * indicates p < 0.0001 compared with other groups
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Page 6 of 9the effects of hTERTp/CMV-regulated TK/CD system in
five tumor cell lines and found that adding CMV enhan-
cer increases TK/CD expression level by 3~26 times
without affecting hTERTp-mediated targeting. Further
study in HeLa cells [12] has revealed that enhancers can
improve hTERT promoter activity by 6~13 times,
among which SV40-CMV dual enhancer/hTERT promo-
ter has the highest activity, which is nearly 3-fold of
CMV enhancer/hTERT promoter; two hTERTp regu-
lated CD/TK fusion suicideg e n ed r i v e nb yS V 4 0 / C M V
dual enhancer has very high specificity and efficacy to
tumor cells. Other vectors have also been used in cancer
gene therapy. Song [27] has applied SB system, in which
TK gene expression is targeted to cancer cells by
hTERTp and enhanced by SV40 enhancer, to selectively
kill liver cancer cells. In the present paper, TK was
fused to EGFP for conventional observation of transfec-
tion efficiency. In addition, because hTERT only
expressed in telomerase positive cells, stronger fluores-
cent signal reflect the relative expression of TK protein,
indicating that we have successfully constructed a CMV
enhanced-, hTERTp driven-TK gene expression vector,
pGL3-basic-hTERTp-TK-EGFP-CMV and increased the
activity of hTERT promoter and expression of its down-
stream TK gene.
Our results indicate that transfection of the enhanced
pGL3-basic-hTERTp-TK-EGFP-CMV with GCV treat-
ment significantly inhibits the survival rate of nasophar-
yngeal carcinoma 5-8F cells and the progress of
nasopharyngeal xenograft in nude mice, and the
enhanced pGL3-basic-hTERTp-TK-EGFP-CMV/GCV
has much better tumor killing efficacy than pGL3-basic-
hTERTp-TK-EGFP/GCV in both NPC 5-8F and MCF-7
cells. Quantitative fluorescence PCR showed that TK
expression level was increased by 2 to 5-fold in NPC 5-
8F and MCF-7 cells transfected with the enhanced vec-
tor compared with that in the cells transfected with
non-enhanced vector. By contrast, TK expression was
not altered by transfection of the enhanced vector in tel-
omerase negative ECV cells. No side effects on liver and
kidney by pathological examination were observed in
in vivo experiment, suggesting the effects of the
enhanced vector is specific to tumor cells and it is safe
in in vivo application.
Figure 4 Tumor inhibition of pGL3-basic-hTERTp-TK-EGFP-CMV/GCV in nude mice with NPC xenograft. Shown are the NPC xenograft in
nude mice without treatment (a), injected with GCV and the non-enhanced plasmid (b), injected with GCV and the enhance plasmid (c),
injected with GCV(d), injected with Lipofectamine 2000 (e) and injected with the enhance plasmid without GCV (f).
Table 4 Injection of pGL3-basic- hTERTp-TK- EGFP- CMV/GCV inhibited tumor development in vivo
Sample Animals Tumor volume at day 39 (cm
3) Tumor weight at day 39 (g) Inhibition rate
Blank 5 6.23 ± 0.04 2.68 ± 0.02 /
Non-enhanced group 5 3.51 ± 0.02 1.51 ± 0.01 43.68%*
Enhanced group/GCV 5 2.72 ± 0.02 1.17 ± 0.01 56.34%*
Enhanced group 5 5.80 ± 0.13 2.51 ± 0.05 6.48%*
GCV group 5 5.98 ± 0.09 2.56 ± 0.09 4.32%*
Lipofectamine group 5 5.83 ± 0.14 2.51 ± 0.02 6.41%*
Data are expressed as mean ± standard deviation from three experiments. * indicates p < 0.0001 compared with the other group.
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lated TK expression can enhance the targeted killing of
nasopharyngeal carcinoma cells need to be further
investigated. In our previous study on hTERT-TK
expression vector, the killing effect of TK under hTERT
promoter, which is a much weaker than CMV promoter,
is significantly reduced compared with that of TK under
the non-selective promoter CMV. In consistence with
our other reports [7-9], our results suggest that addition
of CMV promoter can significantly enhance TK efficacy
without changing its targeting controlled by hTERT.
Wang [11,12] proposed that CMV can recognize specific
binding sites of different activators, enhancers and pro-
moters, therefore synergistically and dramatically pro-
motes protein expression. In addition, co-effect of SV40
and CMV enhancers also enhance promoter activity
because SV40 enhancer can effectively increase the
amount of exogenous DNA in the nucleus. Therefore,
the interference between hTERTp and CMV hindered
the efficiency of vector.
In this study, we found that telomerase activities are
significantly reduced in both NPC 5-8F and MCF-7 cells
transfected with the enhanced vector after GCV treat-
ment, but not changed in ECV cells transfected with the
enhanced vector (Figure 4). One possible explanation is
that the reduced telomerase activity in cells transfected
with the enhanced vector is the result of the cell death
induced by TK/GCV. We speculate that in the early
stage of transfection of the enhanced vector, when GCV
was not added into the cells, telomerase activity is tem-
porally increased; after adding GCV into the cells, cell
numbers dramatically decreased resulting in the reduced
telomerase activity. However, we can not exclude other
possibilities. Decreased telomerase activity has been
shown to inhibit tumor proliferation. Transfection of
eukaryotic vector containing antisense of hTERT in
human gastric cancer SGC-7901 cells attenuated telo-
merase activity, reduced telomere length, decreased
expressions of hTERT, bcL-2 and c-myC at mRNA and
protein levels without changing hTR and TP1 expres-
sion, inhibited cell proliferation and arrested the cells in
G0/G1 phase [28]. Injection of SGC-7901 cells trans-
fected with the eukaryotic vector containing antisense of
hTERT did not induce tumor development in nude
mice, whereas injection of control cells without transfec-
tion induced touchable tumor growth. Transfection of
hTERT small interfering RNA had similar results [29].
But it is more plausible that the mechanisms by which
hTERT antisense or siRNA induced tumor apoptosis
through reduced telomerase activity are different from
that of the direct tumor killing of TK gene expression
driven by hTERT promoter.
To our knowledge, the effect of TK gene expression
driven by CMV enhancer/hTERT promoter has not
been previously studied in NPC. In the present study,
we also improved the methodology: 1) We applied co-
expression of TK gene with EGFP in favor of the experi-
mental observation, and adopted real time fluorescence
quantitative PCR to measure t h ed i f f e r e n c ei nT Kg e n e
expression; 2) We studied tumor-inhibitory effect of the
enhanced vector both in vitro and in vivo, and explored
the safety of in vivo application of the enhanced vector;
3) The enhanced vector had similar tumor inhibitory
efficacy in both NPC and MCF-7 cells, suggesting it
might have broader application potentials in other can-
cer therapies; 4) We compared the effect of the
enhanced vector with the single promoter vector to elu-
cidate the increased efficacy of the enhanced vector/
GCV system. As an enhanced targeting vector, transfec-
tion of pGL3-basic-hTERTp-TK-EGFP-CMV has
obvious targeted killing efficacy on nasopharyngeal car-
cinoma and breast cancer, but its application in other
tumor therapies need to be further investigated.
In conclusion, we successfully constructed the
enhanced TK gene expression vector driven by hTERT
promoter and CMV enhancer, and revealed that the
enhanced vector indeed increased the TK expression
and improved its killing efficacy on NPC in vitro and in
vivo, indicating that the enhanced vector has clinical
potentials in nasopharyngeal carcinoma gene therapy.
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